| Literature DB >> 25705847 |
Martin Lauss1, Rizwan Haq2, Helena Cirenajwis1, Bengt Phung3, Katja Harbst1, Johan Staaf1, Frida Rosengren3, Karolina Holm1, Mattias Aine3, Karin Jirström4, Åke Borg1, Christian Busch5, Jürgen Geisler6, Per E Lønning5, Markus Ringnér1, Jillian Howlin3, David E Fisher2, Göran Jönsson7.
Abstract
The microphthalmia-associated transcription factor (MITF) is a key regulator of melanocyte development and a lineage-specific oncogene in melanoma; a highly lethal cancer known for its unpredictable clinical course. MITF is regulated by multiple intracellular signaling pathways, although the exact mechanisms that determine MITF expression and activity remain incompletely understood. In this study, we obtained genome-wide DNA methylation profiles from 50 stage IV melanomas, normal melanocytes, keratinocytes, and dermal fibroblasts and utilized The Cancer Genome Atlas data for experimental validation. By integrating DNA methylation and gene expression data, we found that hypermethylation of MITF and its co-regulated differentiation pathway genes corresponded to decreased gene expression levels. In cell lines with a hypermethylated MITF-pathway, overexpression of MITF did not alter the expression level or methylation status of the MITF pathway genes. In contrast, however, demethylation treatment of these cell lines induced MITF-pathway activity, confirming that gene regulation was controlled via methylation. The discovery that the activity of the master regulator of pigmentation, MITF, and its downstream targets may be regulated by hypermethylation has significant implications for understanding the development and evolvement of melanoma.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25705847 PMCID: PMC4720161 DOI: 10.1038/jid.2015.61
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551